Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$1.87
-6.0%		$3.16
$7.96
▼
$24.15
$9.43M0.6315,685 shs25,406 shs
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
$0.62
-1.8%		$1.44
$0.59
▼
$4.34
$9.49M2.33340,513 shs116,129 shs
Palatin Technologies stock logo
PTN
Palatin Technologies
$4.82
-5.7%		$9.66
$4.58
▼
$31.00
$8.58M0.6335,310 shs28,085 shs
VolitionRX Limited stock logo
VNRX
VolitionRX
$0.18
+2.6%		$0.29
$0.16
▼
$9.50
$2.38M1.171.43 million shs542,241 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00%-6.50%-35.96%-47.77%-60.80%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-1.83%-2.73%-48.87%-76.01%-84.71%
Palatin Technologies stock logo
PTN
Palatin Technologies
-5.68%-19.53%-52.28%-37.24%+481,999,900.00%
VolitionRX Limited stock logo
VNRX
VolitionRX
+2.58%+2.76%-31.04%-79.02%-97.99%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$1.87
-6.0%		$3.16
$7.96
▼
$24.15
$9.43M0.6315,685 shs25,406 shs
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
$0.62
-1.8%		$1.44
$0.59
▼
$4.34
$9.49M2.33340,513 shs116,129 shs
Palatin Technologies stock logo
PTN
Palatin Technologies
$4.82
-5.7%		$9.66
$4.58
▼
$31.00
$8.58M0.6335,310 shs28,085 shs
VolitionRX Limited stock logo
VNRX
VolitionRX
$0.18
+2.6%		$0.29
$0.16
▼
$9.50
$2.38M1.171.43 million shs542,241 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00%-6.50%-35.96%-47.77%-60.80%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-1.83%-2.73%-48.87%-76.01%-84.71%
Palatin Technologies stock logo
PTN
Palatin Technologies
-5.68%-19.53%-52.28%-37.24%+481,999,900.00%
VolitionRX Limited stock logo
VNRX
VolitionRX
+2.58%+2.76%-31.04%-79.02%-97.99%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
1.00
SellN/AN/A
Palatin Technologies stock logo
PTN
Palatin Technologies
3.00
Buy$55.001,041.08% Upside
VolitionRX Limited stock logo
VNRX
VolitionRX
2.40
Hold$28.0015,577.49% Upside

Current Analyst Ratings Breakdown

Latest VNRX, LTRN, ALVR, and PTN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/17/2026
VolitionRX Limited stock logo
VNRX
VolitionRX
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingHold
7/29/2026
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/A$0.58 per shareN/A
Palatin Technologies stock logo
PTN
Palatin Technologies
$4.49M1.91N/AN/A$5.95 per share0.81
VolitionRX Limited stock logo
VNRX
VolitionRX
$1.73M1.41N/AN/A($5.30) per share-0.03
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$17.12M-$1.62N/AN/AN/AN/A-368.02%-148.62%11/11/2026 (Estimated)
Palatin Technologies stock logo
PTN
Palatin Technologies
-$17.31MN/AN/AN/AN/AN/A-141.40%-58.08%11/16/2026 (Estimated)
VolitionRX Limited stock logo
VNRX
VolitionRX
-$23.36M-$0.56N/AN/AN/A-1,043.12%N/A-303.75%11/12/2026 (Estimated)

Latest VNRX, LTRN, ALVR, and PTN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q1 2027
Palatin Technologies stock logo
PTN
Palatin Technologies
-$0.42N/AN/AN/A$2.51 millionN/A
11/12/2026Q3 2026
VolitionRX Limited stock logo
VNRX
VolitionRX
-$0.35N/AN/AN/A$0.71 millionN/A
11/11/2026Q3 2026
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$0.35N/AN/AN/AN/AN/A
9/28/2026Q4 2026
Palatin Technologies stock logo
PTN
Palatin Technologies
-$1.20-$1.11+$0.09N/A$1.50 million$0.30 million
8/14/2026Q2 2026
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
-$0.38-$0.57-$0.19-$0.57N/AN/A
8/13/2026Q2 2026
VolitionRX Limited stock logo
VNRX
VolitionRX
-$0.5675-$0.85-$0.2825-$0.85$0.42 million$0.40 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/AN/AN/AN/AN/A
Palatin Technologies stock logo
PTN
Palatin Technologies
N/AN/AN/AN/AN/A
VolitionRX Limited stock logo
VNRX
VolitionRX
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
N/A
1.96
1.96
Palatin Technologies stock logo
PTN
Palatin Technologies
N/A
5.04
5.04
VolitionRX Limited stock logo
VNRX
VolitionRX
N/A
0.30
0.30

Institutional Ownership

CompanyInstitutional Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
28.62%
Palatin Technologies stock logo
PTN
Palatin Technologies
11.50%
VolitionRX Limited stock logo
VNRX
VolitionRX
8.09%

Insider Ownership

CompanyInsider Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
8.78%
Palatin Technologies stock logo
PTN
Palatin Technologies
7.10%
VolitionRX Limited stock logo
VNRX
VolitionRX
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionNo Data
Lantern Pharma Inc. stock logo
LTRN
Lantern Pharma
1614.94 million13.63 millionOptionable
Palatin Technologies stock logo
PTN
Palatin Technologies
251.78 million1.65 millionN/A
VolitionRX Limited stock logo
VNRX
VolitionRX
7513.65 million12.71 millionNot Optionable

Recent News About These Companies

VolitionRx stock: VolitionRx grants 12,000 RSUs to marketing chief
October 23, 2026  |  ad-hoc-news.deA
VolitionRX Ltd
October 20, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/vnrx-volitionrx-ltd/vitals
Nasdaq cuts target for VolitionRx stock to USD 13.89 from USD 16.83
October 20, 2026  |  ad-hoc-news.deA
VolitionRX (NYSEAMERICAN:VNRX) Stock Breaks Below 50 Day Moving Average - What's Next?
October 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31128061
VolitionRx consensus price target decreased by 17.44% to $13.89
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/volitionrx-consensus-price-target-decreased-by-17-44-to-13-89/ar-AA2dpGf4
VolitionRx stock faces a data driven trading reset
September 22, 2026  |  ad-hoc-news.deA
VolitionRx Limited stock edges higher as investors weigh recent results
September 18, 2026  |  ad-hoc-news.deA
MissionIRNewsBreaks – VolitionRx (NYSE American: VNRX) Joins €6.3 Million French Government-Funded DETECSEPS Sepsis Project
September 17, 2026  |  financialcontent.comF
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
September 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/volitionrx-shares-further-details-and-video-of-the-detecseps-program-launch-in-france-302881991.html
VolitionRx Participates in Launch of DETECSEPS Program in France
September 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/volitionrx-participates-in-launch-of-detecseps-program-in-france-302881882.html
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
September 14, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/volitionrx-limited-announces-pre-payment-in-full-of-7-5-million-senior-secured-convertible-promissory-note-due-may-20--2027--302877586.html
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
September 10, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/volition-presents-early-stage-i-solid-cancer-detection-at-the-esmo-map-conference-302875069.html
VolitionRX Earnings Call: Scientific Momentum Meets Cash Risks
August 26, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/volitionrx-earnings-call-scientific-momentum-meets-cash-risks?utm_source=marketbeat.com&utm_medium=referral
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
August 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/volitionrx-highlights-commercial-momentum-and-multi-pillar-execution-across-27-billion-total-addressable-markets-302860413.html
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
August 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/volition-announces-landmark-clinical-validation-of-nuq-nets-biomarker-in-sepsis-302860395.html
Volition (VNRX) Q2 2026 Earnings Call Transcript
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/volition-vnrx-q2-2026-earnings-232839236.html
Volitionrx Ltd Stock Price History
August 20, 2026  |  investing.comhttps://www.investing.com/equities/volitionrx-ltd-historical-data
VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936883-volitionrx-limited-vnrx-q2-2026-earnings-call-transcript
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
August 13, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/volitionrx-limited-announces-second-quarter-2026-financial-results-and-business-update-302850844.html
VolitionRx Limited (VNRX) Stock Major Holders - Yahoo Finance
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VNRX/holders/

New MarketBeat Followers Over Time

Media Sentiment Over Time

AlloVir stock logo

AlloVir NASDAQ:ALVR

$1.87 -0.12 (-6.03%)
As of 10/23/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Lantern Pharma stock logo

Lantern Pharma NASDAQ:LTRN

$0.62 -0.01 (-1.83%)
Closing price 10/26/2026 04:00 PM Eastern
Extended Trading
$0.65 +0.03 (+4.36%)
As of 05:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Palatin Technologies stock logo

Palatin Technologies NYSEAMERICAN:PTN

$4.82 -0.29 (-5.68%)
Closing price 10/26/2026 04:00 PM Eastern
Extended Trading
$4.83 +0.01 (+0.12%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

VolitionRX stock logo

VolitionRX NYSEAMERICAN:VNRX

$0.18 +0.00 (+2.58%)
Closing price 10/26/2026 04:10 PM Eastern
Extended Trading
$0.19 +0.01 (+5.82%)
As of 06:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas